Company intelligence / Profile preview

Black Diamond Studio

Cambridge, Massachusetts, United Statesblackdiamond501.com ↗

Ownership: Private
Development stage: Other

Overview

Black Diamond Therapeutics develops precision oncology therapies targeting families of oncogenic mutations. Its lead program, BDTX‑1535, a brain‑penetrant small molecule EGFR inhibitor, entered Phase 2 trials for non-classical EGFR mutant NSCLC and has shown encouraging safety and pharmacokinetic data in glioblastoma. The company recently licensed its RAF inhibitor BDTX‑4933 to Servier after deprioritizing internal development.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Servier

Beyond the preview

Go deeper on Black Diamond Studio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Black Diamond Studio.

Explore the full profile